Y
Yu-Tzu Tai
Researcher at Harvard University
Publications - 352
Citations - 26090
Yu-Tzu Tai is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bone marrow. The author has an hindex of 82, co-authored 327 publications receiving 22833 citations. Previous affiliations of Yu-Tzu Tai include Dana Corporation & Chung Shan Medical University.
Papers
More filters
Journal ArticleDOI
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies,Noopur Raje,Noopur Raje,Noopur Raje,Teru Hideshima,Teru Hideshima,Teru Hideshima,Suzanne Lentzsch,Suzanne Lentzsch,Suzanne Lentzsch,Gloria Young,Gloria Young,Gloria Young,Yu-Tzu Tai,Yu-Tzu Tai,Yu-Tzu Tai,Boris Lin,Boris Lin,Boris Lin,Klaus Podar,Klaus Podar,Klaus Podar,Deepak K. Gupta,Deepak K. Gupta,Deepak K. Gupta,Dharminder Chauhan,Dharminder Chauhan,Dharminder Chauhan,Steven P. Treon,Steven P. Treon,Steven P. Treon,Paul G. Richardson,Paul G. Richardson,Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Robert L. Schlossman,Gareth J. Morgan,Gareth J. Morgan,Gareth J. Morgan,George W. Muller,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson,Kenneth C. Anderson +48 more
TL;DR: In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Journal ArticleDOI
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima,Dharminder Chauhan,Dharminder Chauhan,Yoshihito Shima,Yoshihito Shima,Noopur Raje,Noopur Raje,Faith E. Davies,Faith E. Davies,Yu-Tzu Tai,Yu-Tzu Tai,Steven P. Treon,Steven P. Treon,Boris Lin,Boris Lin,Robert L. Schlossman,Robert L. Schlossman,Paul G. Richardson,Paul G. Richardson,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson +24 more
TL;DR: Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.
Journal ArticleDOI
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more
TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.
Journal ArticleDOI
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften,Gillian L. Dalgliesh,Helen Davies,Lina Chen,Graham R. Bignell,Christopher Greenman,Sarah Edkins,Claire Hardy,Sarah O’Meara,Jon W. Teague,Adam Butler,Jonathan Hinton,Calli Latimer,Jenny Andrews,Syd Barthorpe,Dave Beare,Gemma Buck,Peter J. Campbell,Jennifer Cole,Simon A. Forbes,Mingming Jia,David T. Jones,Chai Yin Kok,Catherine Leroy,Meng-Lay Lin,David J. McBride,Mark Maddison,Simon Maquire,Kirsten McLay,Andrew Menzies,Tatiana Mironenko,Lee Mulderrig,Laura Mudie,Erin Pleasance,Rebecca Shepherd,Raffaella Smith,Lucy Stebbings,Philip J. Stephens,Gurpreet Tang,Patrick S. Tarpey,Rachel Turner,Kelly Turrell,Jennifer Varian,Sofie West,Sara Widaa,Paul Wray,V. Peter Collins,Koichi Ichimura,Simon Law,John Wong,Siu Tsan Yuen,Suet Yi Leung,Giovanni Tonon,Giovanni Tonon,Ronald A. DePinho,Yu-Tzu Tai,Kenneth C. Anderson,Richard J. Kahnoski,Aaron Massie,Sok Kean Khoo,Bin Tean Teh,Michael R. Stratton,Michael R. Stratton,P. Andrew Futreal +63 more
TL;DR: UTX reintroduction into cancer cells with inactivating UTX mutations resulted in slowing of proliferation and marked transcriptional changes, identifying UTX as a new human cancer gene.
Journal ArticleDOI
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli,Hervé Avet-Loiseau,David C. Wedge,Peter Van Loo,Ludmil B. Alexandrov,Inigo Martincorena,Kevin J. Dawson,Francesco Iorio,Serena Nik-Zainal,Graham R. Bignell,Jonathan Hinton,Yang Li,Jose M. C. Tubio,Stuart McLaren,Sarah O' Meara,Adam Butler,Jon W. Teague,Laura Mudie,Elizabeth Anderson,Naim U. Rashid,Yu-Tzu Tai,Masood A. Shammas,Adam S. Sperling,Mariateresa Fulciniti,Paul G. Richardson,Giovanni Parmigiani,Florence Magrangeas,Stephane Minvielle,Philippe Moreau,Michel Attal,Thierry Facon,P. Andrew Futreal,Kenneth C. Anderson,Peter J. Campbell,Nikhil C. Munshi +34 more
TL;DR: The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.